Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

Baorui Liu

2011-01-01

Journal of Modern Oncology

Abstract:Objective:Despite the success of docetaxel as an anti-tumor agent,the inter-individual variability in drug response still poses a major impediment on further use of this agent in the treatment of cancer.As some patients are inherent or acquired-resistance to this drug,biomarkers are desired to stratify patients into groups of different likelihood of the tumor response before chemotherapy,thus maximizing effects and minimizing toxicities of chemotherapy.Our current study focus on two promising biomarkers,BRCA1(breast cancer susceptibility gene 1) and β-tubulin Ⅲ.To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases,we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with docetaxel sensitivity.Methods: Real-time quantitative PCR was used to test related genes expression in forty-one malignant effusions prospectively collected.Viable tumor cells obtained from malignant effusions were tested for sensitivity to docetaxel using ATP-TCA assay.Results: BRCA1 expression level was positively correlated with sensitivity to docetaxel in non small cell lung cancer(NSCLC)(P=0.008) and gastric cancer patients(P=0.032),meanwhile β-tubulin Ⅲ expression level was inversely correlated with sensitivity to doxetaxel in malignant effusions of NSCLC patients(P=0.022).No significant interaction was found between BRCA1 and β-tubulin Ⅲ mRNA expressions on sensitivity to docetaxel(P0.05).Conclusion: Our results demonstrated that BRCA1 and β-tubulin III mRNA expression level in malignant effusions,in which all cancer cells were metastatic,were correlated with docetaxel sensitivity.Meanwhile,BRCA1 may be a better predictive marker for chemosensitivity to doxetaxel than β-tubulin Ⅲ.At the cost of a centesis,it may be possible to acquire a limited genomic portrait of tumor in some patients with malignant effusions,enabling the development of real-time individualized chemotherapy while tumor progression.